# Equecabtagene Autoleucel: First Approval

Source: https://onco.cc/key-papers/paper-keam-mol-diagn-ther/  
OnCo record `paper-keam-mol-diagn-ther` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one treatment page, indexed on Europe PMC as PubMed record 37658205 and published in Molecular diagnosis & therapy; the citing page links this DOI, which is how the record was matched.

## Summary

Equecabtagene autoleucel (Fucaso ®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy that uses lentivirus as a gene vector to transfect autologous T cells, is being developed by IASO Biotechnology and Innovent Biologics, Inc. for the treatment of multiple myeloma (MM) and autoimmune diseases of the nervous system, including neuromyelitis optica spectrum disorder (NMOSD). Equecabtagene autoleucel was granted conditional approval in China in June 2023 for the treatment of adults with relapsed or refractory MM (RRMM) who have progressed after ≥ 3 lines of therapy (≥ 1 proteasome inhibitor and an immunomodulator). This article summarizes the milestones in the development of equecabtagene autoleucel leading to this first approval in patients with RRMM who have progressed after multiple lines of therapy.

Indexed on Europe PMC as PubMed record 37658205 (DOI 10.1007/s40291-023-00673-y). Matched by DOI alone: one treatment page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Molecular diagnosis & therapy
- Year: 2023
- DOI: 10.1007/s40291-023-00673-y
- Authors: Keam SJ
- What it means: One treatment page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Mol Diagn Ther 2023: https://doi.org/10.1007/s40291-023-00673-y
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37658205/
- Europe PMC: https://europepmc.org/article/MED/37658205

## Connected records

- drugs: [Equecabtagene autoleucel](https://onco.cc/drugs/equecabtagene-autoleucel/)

---
JSON: https://onco.cc/api/v1/entities/paper-keam-mol-diagn-ther.json